Page last updated: 2024-12-10

isepamicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3037209
CHEMBL ID272080
SCHEMBL ID18763321
SCHEMBL ID21838768
MeSH IDM0067297

Synonyms (50)

Synonym
hapa-b
isepalline
sch-21420
D02545
isepamicin (usan/inn)
58152-03-7
sch 21420
isepamicin
hapa-gentamycin b
(s)-o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1.4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1.6))-1,3-diamino-n1-(3-aminolactoyl)-1,2,3-trideoxy-d-scyllo-inositol
d-streptamine, o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->6))-n(sup 1)-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (s)-
d-streptamine, o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-n1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (s)-
isepamicina [spanish]
ccris 1919
isepamicin [usan:inn:ban]
isepamicinum [latin]
o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->6))-2-deoxy-n(sup 1)-((s)-isoseryl)-d-streptamine
brn 4896716
einecs 261-143-4
d-streptamine, o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-n(sup 1)-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (s)-
o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-2-deoxy-n(sup 1)-((s)-isoseryl)-d-streptamine
isepamicine [french]
CHEMBL272080
(2s)-3-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-2-[(2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxypropanamide
unii-g7k224460p
g7k224460p ,
isepamicine
isepamicina
isepamicinum
isepamicin [mi]
isepamicin [inn]
o-6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-2-deoxy-n(sup 1)-((s)-isoseryl)-d-streptamine
isepamicin [mart.]
isepamicin [usan]
isepamicin [who-dd]
isepamicin [jan]
1-n-((s)-3-amino-2-hydroxypropionyl)gentamicin b
d-streptamine, o-6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-n(sup 1)-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (s)-
DTXSID1048380
SCHEMBL18763321
(2s)-3-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-{[(2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-2-{[(2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxypropanimidic acid
NCGC00164587-04
(s)-3-amino-n-((1r,2s,3s,4r,5s)-5-amino-4-((2r,3r,4s,5s,6r)-6-(aminomethyl)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yloxy)-2-((2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2h-pyran-2-yloxy)-3-hydroxycyclohexyl)-2-hydroxypropanamide
DB13540
isepamicinsulphate
SCHEMBL21838768
HY-106668
CS-0026304
gtpl12136
AKOS040758207

Research Excerpts

Overview

Isepamicin is a new semisynthetic aminoglycoside derived from gentamicin B and it is effective against Gram negative bacteria. It has a significantly low nephro as well as ototoxicity in animals and is expected to have a clinical efficacy comparable to amikacin.

ExcerptReferenceRelevance
"Isepamicin is a new semisynthetic aminoglycoside derived from gentamicin B and it is effective against Gram negative bacteria. "( Investigation of isepamicin in vitro efficiency in Gram negative bacteria efficacy of isepamicin.
Ali, HB; Asuman, B; Kubra, HU; Sarah, AF; Sreylis, N; Yeliz, TC, 2021
)
2.4
"isepamicin is a new aminoglycoside with a spectrum of activity similar to amikacin with an advantage of possessing a high level of stability against different aminoglycoside modifying enzymes. "( In vitro susceptibility of nosocomial isolates against a new aminoglycoside isepamicin.
Bali, R; Das, BK; Kapil, A, 2001
)
1.98
"Isepamicin is a newly introduced aminoglycoside in Taiwan. "( In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
Chang, SC; Feng, NH; Hsueh, PR; Tsai, TY; Wang, JT, 2007
)
2.1
"Isepamicin is a semi-synthetic aminoglycoside with a significantly low nephro as well as ototoxicity in animals and which is expected to have a clinical efficacy comparable to that of amikacin."( In vitro activity of isepamicin (Sch 21420), a new aminoglycoside.
Qadri, SM; Saldin, H; Tullo, D; Ueno, Y,
)
1.17
"Isepamicin is a new aminoglycoside with in-vitro activity superior to amikacin. "( Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
Blaise, D; Cordonnier, C; Espinouse, D; Herbrecht, R; Leblond, V; Minozzi, C; Sadoun, A; Sauvage, C, 1995
)
3.18
"Isepamicin is a new aminoglycoside antibiotic which has a superior stability to aminoglycoside-inactivating enzymes compared with other available aminoglycosides. "( The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Colardyn, F, 1995
)
2.03
"Isepamicin is a new aminoglycoside antibiotic which possesses greater stability to aminoglycoside-inactivating enzymes compared with other available aminoglycosides. "( Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
Beaucaire, G, 1995
)
2
"Isepamicin is a new aminoglycoside that has activity against many bacteria resistant to other aminoglycosides. "( Pharmacokinetics of isepamicin.
Affrime, MB; Barr, WH; Colucci, R; Cutler, D; Elliott, M; Lin, CC; Radwanski, E; Zampaglione, N, 1995
)
2.06
"Isepamicin is a new aminoglycoside antibiotic with activity against both gram-negative and gram-positive bacteria. "( Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers.
Affrime, M; Batra, V; Cayen, MN; Christopher, D; Cutler, D; Korduba, C; Lin, CC; Nomeir, AA; Radwanski, E, 1997
)
2.02
"Isepamicin is an aminoglycoside antibacterial with properties similar to those of amikacin, but with better activity against strains producing type I 6'-acetyltransferase. "( Clinical pharmacokinetics and pharmacodynamics of isepamicin.
Padoin, C; Petitjean, O; Tod, M, 2000
)
2
"Isepamicin is a new aminoglycoside, derived from gentamicin B, which is more stable than other aminoglycosides against inactivating enzymes, and is less nephrotoxic. "( Once daily isepamicin treatment in complicated urinary tract infections.
Chen, YS; Lee, SS; Lin, HH; Lin, WR; Liu, YC; Tsai, TH; Wann, SR; Yen, MY, 1999
)
2.14
"Isepamicin is a broad-spectrum aminoglycoside, a derivative of gentamicin B."( [Mechanisms of resistance to dactimicin and isepamicin in clinical strains of gram-negative rods isolated in Czechoslovakia].
Inouye, S; Kettner, M; Miller, GH, 1992
)
1.27
"Isepamicin is a new aminoglycoside drug derived from gentamicin, which is more stable than other aminoglycosides to inactivating enzymes and experimentally is less nephrotoxic than gentamicin or amikacin. "( Post-antibiotic effect of isepamicin compared to that of other aminoglycosides.
Agra, M; Lurueña, S; Minguez, F; Prieto, J; Ramos, C, 1990
)
2.02
"Isepamicin sulfate is a new aminoglycoside antibiotic currently undergoing clinical investigation."( Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin.
Bagger-Sjöbäck, D; Harada, Y; Hirakawa, K; Nikaido, M; Nishida, I; Takumida, M, 1990
)
1.21

Effects

ExcerptReferenceRelevance
"Isepamicin, which has a secondary amino group at Position 3", may only be able to interact at Position 3 and enzyme-isepamicin complexes are likely to be less stable."( The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups.
Hare, RS; Miller, GH; Naples, L; Sabatelli, FJ; Shaw, KJ, 1995
)
1.24
"Isepamicin, which has a secondary amino group at Position 3", may only be able to interact at Position 3 and enzyme-isepamicin complexes are likely to be less stable."( The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups.
Hare, RS; Miller, GH; Naples, L; Sabatelli, FJ; Shaw, KJ, 1995
)
1.24

Toxicity

The proportion of patients reporting any adverse event was comparable between the isepamicin (13%) and amikacin (11%) groups. Treatment-related adverse were mainly mild or moderate in severity. Adverse events were reported in 12% of patients in the isEpamicin group and 6% in the amikACin group.

ExcerptReferenceRelevance
" Intravenous LD50 values of HAPA-B were 234 mg/kg in male and 236 mg/kg in female for mice, 489 mg/kg in male and 476 mg/kg in female for rats and 720-864 mg/kg for dogs."( [Toxicological studies on isepamicin (HAPA-B). I. Acute toxicity test in the mouse, rat and dog].
Hara, H; Hara, T; Iizuka, K; Matsumoto, K; Morino, T; Motoyama, K; Sano, K; Yamamoto, H, 1986
)
0.57
" Fourteen per cent of isepamicin and 11% of amikacin patients experienced adverse events."( The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Colardyn, F, 1995
)
0.9
" Treatment-related adverse were mainly mild or moderate in severity and occurred in 10% of isepamicin patients and 13% of amikacin patients."( Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
Covi, M; Velluti, G, 1995
)
0.78
" Adverse events were reported in 12% of patients in the isepamicin group and 6% in the amikacin group."( Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
Esparza-Ahumada, S; Morfin-Otero, R; Rodriguez-Noriega, E, 1995
)
0.8
" Nine per cent of patients reported at least on adverse event during the study."( Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections.
Giamarellou, H; Pefanis, A; Petrikkos, G; Tsagaraki, C, 1995
)
0.56
" The proportion of patients experiencing at least one adverse event was 11%, 25% and 9% for isepamicin once daily, isepamicin twice daily and amikacin, respectively."( Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
Beaucaire, G, 1995
)
0.78
" Overall, the proportion of patients reporting any adverse event was comparable between the isepamicin (13%) and amikacin (11%) groups."( An overview of the safety of isepamicin in adults.
Blum, D, 1995
)
0.8

Pharmacokinetics

Isepamicin is not metabolised and is eliminated solely via the renal route with an elimination half-life (t 1/2 beta) of 2 to 3 hours in adults with normal renal function.

ExcerptReferenceRelevance
"Bactericidal activities of isepamicin and ofloxacin against Pseudomonas aeruginosa E7 were examined using an in vitro computer programmed pharmacokinetic simulation system."( [Bactericidal activities of isepamicin and ofloxacin against Pseudomonas aeruginosa evaluated using an in vitro pharmacokinetic simulation system].
Goto, S; Kaneko, Y; Tsuji, A; Yamaguchi, K, 1994
)
0.88
" Thus peak plasma concentrations and area under the plasma concentration curve (AUC) values are proportional to the administered dose while clearance (1."( Pharmacokinetics of isepamicin.
Affrime, MB; Barr, WH; Colucci, R; Cutler, D; Elliott, M; Lin, CC; Radwanski, E; Zampaglione, N, 1995
)
0.61
" Neonates up to the age of 16 days (Group IV) showed a distinctly different pharmacokinetic profile: a significantly larger AUC, longer half-life, lower Cmax and lower total body clearance."( Pharmacokinetics of isepamicin in paediatric patients.
Affrime, M; Colucci, R; Cutler, D; Elliott, M; Guerciolini, R; Lin, CC; Radwanski, E; Scaglione, F; Viganò, A; Zampaglione, N, 1995
)
0.61
" Compared with healthy volunteers, the mean values of the PK parameters were profoundly modified in ICU patients: elimination clearance was reduced by 48%, the volume of distribution in the central compartment (Vc) was increased by 50%, the peripheral volume of distribution was 70% higher, the distribution clearance was 146% lower, and the elimination half-life was ca."( Population pharmacokinetic study of isepamicin with intensive care unit patients.
Cougnard, J; Minozzi, C; Padoin, C; Petitjean, O; Tod, M, 1996
)
0.57
" As age increased, there were increases in the elimination phase half-life (t1/2 beta) and the area under the plasma concentration-time curve extrapolated to infinity (AUC0-infinity), and decreases in systemic (Cl) and renal clearance (Clr)."( Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers.
Affrime, M; Batra, V; Cayen, MN; Christopher, D; Cutler, D; Korduba, C; Lin, CC; Nomeir, AA; Radwanski, E, 1997
)
0.58
" Pharmacokinetic parameters were independent of the dosage in the range 15-25 mg/kg and were not different in the patients treated for 5 or 10 days."( Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study.
Beaucaire, G; Cougnard, J; Minozzi, C; Petitjean, O; Ponsonnet, D; Tod, M, 1999
)
1.75
" Isepamicin is not metabolised and is eliminated solely via the renal route with an elimination half-life (t 1/2 beta) of 2 to 3 hours in adults with normal renal function."( Clinical pharmacokinetics and pharmacodynamics of isepamicin.
Padoin, C; Petitjean, O; Tod, M, 2000
)
1.47
" Pharmacokinetic parameters were similar for the two groups with large interindividual variations."( Comparison of two methods to obtain a desired first isepamicin peak in intensive care patients.
Coulaud, JM; Fauvelle, F; Lecointre, K; Poussel, JF; Tardy, D; Trape, G, 2001
)
0.56
" Such changes are consistent with a significant increase in the Cmax concentrations (45 vs 50 mg/L, and 38 vs 49 mg/L) and in the AUC (136 vs 158 and 137 vs 162 mg/L."( Key pharmacokinetic parameters of isepamicin in febrile neutropenic cancer patients and in women with acute pelvic inflammatory disease.
Gala, JL; Leal, T; Vandercam, B; Wallemacq, P; Yombi, JC, 2005
)
0.61
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Once-daily dosing with isepamicin is as effective as twice- daily doses with amikacin. The initial dosage of 15 mg/kg appeared to be adequate, but the dosage interval should be determined by monitoring residual isepsamicin concentrations in plasma.

ExcerptRelevanceReference
" The results of this study suggest that no additional dosage adjustment of isepamicin during concomitant therapy with piperacillin in hemodialysis patients is necessary."( Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease.
Affrime, MB; Awni, WM; Halstenson, CE; Heim-Duthoy, KL; Herman, CS; Keane, WF; Kelloway, JH; Teal, MA; Wong, MO, 1992
)
0.74
" These results support the idea that the major significance of the PAE is in its application to dosing regimens."( In vivo postantibiotic effect of isepamicin and other aminoglycosides in a thigh infection model in neutropenic mice.
Caminero, MM; Fuentes Martinez, F; Izquierdo Izquierdo, J; Minguez Minguez, F; Prieto Prieto, J, 1992
)
0.56
" These data indicate that dosage adjustments are necessary in subjects with decreased renal function."( Isepamicin disposition in subjects with various degrees of renal function.
Affrime, MB; Awni, WM; Halstenson, CE; Kelloway, JS; Lin, CC; Shapiro, BE; Teal, MA, 1991
)
1.72
"To investigate the possible effect of the dosing scheme of aminoglycosides on their concentration in the cochlear tissue, we gave two groups of 12 guinea pigs subcutaneous doses of 45 mg of isepamicin (ca."( Effect of isepamicin dosing scheme on concentration in cochlear tissue.
Claes, J; De Broe, ME; Derde, MP; Govaerts, PJ; Kaufman, L; Marquet, JF; Van de Heyning, PH, 1991
)
0.87
"In order to reduce the dosage of aminoglycoside in the treatment of patients with complicated urinary tract infections (UTI) in outpatient clinics and to improve cost benefits, we tried both ofloxacin (OFX) treatment and a combination treatment with OFX and a single dose of aminoglycoside (isepamicin)."( Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside.
Eto, K; Ishii, T; Kumazawa, J; Matsumoto, T; Saito, Y; Sawae, Y; Ueda, S; Yushita, Y, 1991
)
0.46
"The effect of the dosing schedule on aminoglycoside ototoxicity was investigated in the guinea pig."( Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin.
Bagger-Sjöbäck, D; Harada, Y; Hirakawa, K; Nikaido, M; Nishida, I; Takumida, M, 1990
)
0.49
" Dose-response effects of HAPA-B on offspring were not observed in the postnatal study."( [Effect of isepamicin (HAPA-B) on reproduction. II. Teratological study in rats (intramuscular administration)].
Kawaguchi, K; Kobayashi, Y; Sasaki, M; Yamada, H; Yamamoto, H, 1986
)
0.66
" Maximum plasma concentrations (Cmax) of HAPA-B after intramuscular, intravenous and drip intravenous administration depended on dosage levels."( [Studies on the metabolic fate of isepamicin sulfate (HAPA-B). IV. Intramuscular, intravenous and drip intravenous administration of HAPA-B in dogs].
Endo, S; Morishita, M; Serizawa, K; Shirai, M; Suzuki, T, 1987
)
0.55
" Shapes of plasma concentration curves after multiple administrations of HAPA-B were very similar to those after single administrations at all dosage levels tested."( [Studies on the metabolic fate of isepamicin sulfate (HAPA-B). V. Plasma concentrations of HAPA-B in dogs after multiple administrations].
Endo, S; Morishita, M; Nakanishi, D; Sakai, A; Shirai, M; Somiya, Y; Suzuki, T, 1987
)
0.55
"A total of 34 patients with intractable chronic respiratory tract infections were treated with isepamicin and/or piperacillin in different dosage regimens."( The administration regimen of isepamicin in patients with chronic respiratory tract infection.
Hara, K; Kobayashi, H; Koga, H; Kohno, S; Konno, M; Nasu, M; Saito, A; Shimizu, K; Soejima, R,
)
0.64
"5 h was independent of the dosage regimen."( Pharmacokinetics of intravenously administered isepamicin in men.
Affrime, M; Cayen, M; Korduba, C; Lin, CC; Radwanski, E, 1995
)
0.55
" Isepamicin was administered once daily with the daily dosage stratified according to the severity of infection: 15 mg/kg isepamicin for severe potentially systemic infections (53 patients) or 8 mg/kg isepamicin for less severe and localised infections (56 patients)."( Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections.
Giamarellou, H; Pefanis, A; Petrikkos, G; Tsagaraki, C, 1995
)
1.47
"The pharmacodynamic characteristics of isepamicin and other aminoglycosides, both in terms of efficacy and toxicity, explain why once-daily administration of these agents should be the optimal dosing regimen."( Once-daily versus multiple-daily dosing of aminoglycosides.
Craig, WA, 1995
)
0.56
" It is completely eliminated via the renal route; consequently dosing in patients with renal insufficiency has to be adjusted according to the degree of renal impairment."( Pharmacokinetics of isepamicin.
Affrime, MB; Barr, WH; Colucci, R; Cutler, D; Elliott, M; Lin, CC; Radwanski, E; Zampaglione, N, 1995
)
0.61
" Therefore, in adult patients with a wide range of infections requiring aminoglycoside therapy, once-daily dosing with isepamicin is as effective as twice- daily dosing with amikacin."( Overview of the efficacy of isepamicin in the adult core clinical trial programme.
Carbon, C, 1995
)
0.79
"5 mg/kg of body weight twice daily or amikacin the same dosage regimen for the treatment of various infections in neutropenic and non-neutropenic paediatric patients were compared in a prospective randomised trial."( A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients.
Principi, N; Viganò, A, 1995
)
0.59
"7 h, was independent of the dosage regimen."( Pharmacokinetics of intramuscularly administered isepamicin in man.
Affrime, M; Cayen, MN; Korduba, C; Lin, CC; Radwanski, E,
)
0.39
" Blood samples were collected at specified times after dosing and assayed for isepamicin by a validated radioimmunoassay method."( Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections.
Affrime, M; Batra, V; Cayen, M; Cutler, D; Korduba, C; Lin, CC; Nomeir, A; Radwanski, E, 1997
)
0.85
") have been progressively employed for the design of dosing schedules of antimicrobial agents."( Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli.
Fuentes, F; Gomez-Lus, ML; Izquierdo, J; Martín, MM; Prieto, J, 1998
)
0.55
"We compared the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium after chronic isepamicin therapy for 7 days in 56 anesthetized rabbits."( Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium.
Chung, CW; Jun, JH; Kim, KS; Lee, KH; Shim, JC, 1999
)
0.8
"We studied the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium during chronic isepamicin therapy in rabbits."( Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium.
Chung, CW; Jun, JH; Kim, KS; Lee, KH; Shim, JC, 1999
)
0.8
" Patients were randomized in four groups with respect to the following isepamicin dosing regimens: (i) 15 mg/kg od for 5 days or (ii) 10 days, (iii) 25 mg/kg on the first day followed by 15 mg/kg od for 4 days or (iv) 9 days."( Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study.
Beaucaire, G; Cougnard, J; Minozzi, C; Petitjean, O; Ponsonnet, D; Tod, M, 1999
)
1.98
" In this group of patients, the initial dosage of 15 mg/kg appeared to be adequate, but the dosage interval should be determined by monitoring residual isepamicin concentrations in plasma."( Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration.
Allaouchiche, B; Boulétreau, P; Breilh, D; Chassard, D; Ducint, D; Jaumain, H; Malbec, I; Saux, MC, 1999
)
0.83
" Cumulative drug dose-response curves were obtained for three different muscles in 24 rabbits."( Neuromuscular blocking effects of the aminoglycoside antibiotics arbekacin, astromicin, isepamicin and netilmicin on the diaphragm and limb muscles in the rabbit.
Hashimoto, Y; Kato, M; Liu, M, 2001
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (89)

Assay IDTitleYearJournalArticle
AID93906Minimum inhibitory concentration (MIC) was measured against Klebsiella pneumoniae.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID529888Induction of apoptosis in pig LLC-PK1 cells at 0.192 to 0.384 mM after 24 hrs electoporated in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Apoptosis induced by aminoglycosides in LLC-PK1 Cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation.
AID523068Activity of Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID522930Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H/D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID30395Minimum inhibitory concentration (MIC) was measured against Acinetobacter baumanni ATCC 19606.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID203165Minimum inhibitory concentration measured against Serratia marcescens1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID326538Antimicrobial activity against Mycobacterium abscessus R39 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID326546Antimicrobial activity against Mycobacterium abscessus R61 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID50539Minimum inhibitory concentration (MIC) was measured against Citrobacter freundii.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID69667Minimum inhibitory concentration (MIC) was measured against Escherichia coli ATCC 35218.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID30415Minimum inhibitory concentration (MIC) was measured against Acinetobacter lwoffi ATCC 17986.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID326537Antimicrobial activity against Mycobacterium abscessus R31 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID326542Antimicrobial activity against Mycobacterium abscessus NTU446 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID326550Antimicrobial activity against Mycobacterium abscessus V120 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID326545Antimicrobial activity against Mycobacterium abscessus R54 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID163279Minimum inhibitory concentration (MIC) was measured against Pseudomonas aeruginosa ATCC 27853.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID206015Minimum inhibitory concentration (MIC) was measured against Staphylococcus aureus ATCC 25923.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID523405Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID326534Antimicrobial activity against Mycobacterium chelonae after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID68538Minimum inhibitory concentration (MIC) was measured against Enterobacter cloacae.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID523067Activity of Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID522928Antibacterial activity against Escherichia coli JM83 producing aminoglycoside 2''-2a phosphotransferase by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID326552Antimicrobial activity against Mycobacterium fortuitum V61 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID523398Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 5 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID523069Activity of Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID326551Antimicrobial activity against Mycobacterium fortuitum V13 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID326549Antimicrobial activity against Mycobacterium abscessus R49 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID405816Antimicrobial activity against Escherichia coli DH5alpha harboring recombinant pIMPAR312007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID326533Antimicrobial activity against Mycobacterium abscessus after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID523397Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID523070Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID326535Antimicrobial activity against Mycobacterium fortuitum after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID522933Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID326548Antimicrobial activity against Mycobacterium abscessus R53 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID523066Antibacterial activity against Escherichia coli JM83 harboring empty pHF022 vector by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID523072Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID326547Antimicrobial activity against Mycobacterium abscessus R65 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID69665Minimum inhibitory concentration (MIC) was measured against Escherichia coli. 1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID405822Antimicrobial activity against Escherichia coli DH5alpha2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID326536Antimicrobial activity against Mycobacterium abscessus CH10 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID326544Antimicrobial activity against Mycobacterium abscessus R50 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID428871Antibacterial activity against Escherichia coli CSH-2 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID522929Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase N196D/D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID326540Antimicrobial activity against Mycobacterium abscessus NTU459 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID326553Antimicrobial activity against Mycobacterium fortuitum V146 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID326543Antimicrobial activity against Mycobacterium abscessus R47 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID428873Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID163280Minimum inhibitory concentration (MIC) was measured against Pseudomonas aeruginosa.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID326541Antimicrobial activity against Mycobacterium abscessus R51 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID67885Minimum inhibitory concentration (MIC) was measured against Enterococcus faecalis ATCC 29212.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID428869Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID522932Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a N196D mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID523071Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID522931Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID428872Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID326539Antimicrobial activity against Mycobacterium abscessus NTU445 isolate after 3 to 5 days by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
AID206014Minimum inhibitory concentration (MIC) was measured against Staphylococcus aureus. 1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID69666Minimum inhibitory concentration (MIC) was measured against Escherichia coli ATCC 25922.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID523396Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID428870Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (166)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (22.29)18.7374
1990's75 (45.18)18.2507
2000's36 (21.69)29.6817
2010's14 (8.43)24.3611
2020's4 (2.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.43 (24.57)
Research Supply Index5.32 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index53.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (16.00%)5.53%
Reviews8 (4.57%)6.00%
Case Studies8 (4.57%)4.05%
Observational0 (0.00%)0.25%
Other131 (74.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]